878486-06-7

Upstream product

• 102281-45-8 p-amino-D-phenylalanine 
• 864739-06-0 (R)-4-amino-3,5-dibromophenylalanine 
• 501-52-0 3-Phenylpropionic acid 

Downstream Products

• 162176-16-1 N²-[4-amino-3,5-dibromo-N-(3-phenyl-1-oxopropyl)-D-phenylalanyl]-N⁶-(phenylmethoxycarbonyl)-L-lysine-2-phenethylamide 
• 864739-07-1 N²-[4-amino-3,5-dibromo-N-(3-phenyl-1-oxopropyl)-D-phenylalanyl]-N⁶-(phenylmethoxycarbonyl)-L-lysine methyl ester 
• 864738-93-2 N²-[4-amino-3,5-dibromo-N-(3-phenyl-1-oxopropyl)-D-phenylalanyl]-N⁶-(phenylmethoxycarbonyl)-L-lysine 
• 864738-92-1 4-amino-3,5-dibromo-N-(3-phenyl-1-oxopropyl)-D-phenylalanine 

Relevant academic research and scientific papers

Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N 2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl) -1-piperidinyl]carbonyl]-D-tyrosyl]-L-ly

Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel